Allure Medical is preparing to launch a Phase 2 trial for its breast cancer treatment for the first time in the United States, according to a news release issued Monday.
The company’s clinical trial will start next week and the company plans to have more details about the trial, including how many patients will participate, on Tuesday.
The trial is being conducted at Allure’s Bellevue, Washington, headquarters, the release said.
It’s one of several that the company is conducting in collaboration with several medical institutions, including the University of Washington and the University at Buffalo.
“Our goal is to provide our patients with the best possible cancer treatment options, including breast cancer, while reducing side effects and improving the quality of life,” said Allure chief executive officer Brian Schmitz in a statement.
The release did not specify how much money Allure plans to invest in the trial.
Allure is not disclosing the trial’s size or scope.
It’s not clear how much Allure has invested in the trials, which were approved in 2016 by the U.S. Food and Drug Administration and the U,S.
Department of Veterans Affairs.
In the company’s other clinical trials, Allure also has a connection to a clinical trial conducted at the University Health Network’s Cancer Institute in the Bronx, New York.
That study, which is also part of Allure, is expected to begin next month.
Allure says it’s planning to launch Phase 3 clinical trials next year and that the trials will test a range of its products, including a range with new cancer treatments.
Schmitz said Allures new breast cancer study will test products from its new line of products, Alluring BioMedic, which will offer a wide range of treatments including hormone therapy, radiotherapy, and surgery.
He also said Alluring will expand its existing clinical trial programs in other countries, and said the company would soon begin the first of the trials in China.
The announcement comes after a news report last week that the National Institutes of Health approved Allure BioMedics for clinical trials in 2017.